CTXR — Citius Pharmaceuticals Share Price
Last trade - 00:00- $120.02m
- $100.28m
- 29
- 36
- 53
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.42 | ||
| Price to Tang. Book | 7.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.28% | ||
| Return on Equity | -42.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 61.72 | 83.59 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
Directors
- Leonard Mazur CHM (76)
- Myron Holubiak PRE (74)
- Jaime Bartushak CFO (54)
- Myron Czuczman EVP (62)
- Ilanit Allen VPR
- Howard Safir LED (75)
- Suren Dutia IND (79)
- Eugene Holuka IND (62)
- William Kane IND (78)
- Carol Webb IND (75)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 9th, 2010
- Public Since
- August 3rd, 2017
- No. of Shareholders
- 92
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 159,094,781
- Address
- 11 Commerce Dr Fl 1, CRANFORD, 07016-3501
- Web
- https://www.citiuspharma.com/
- Phone
- +1 9089676677
- Contact
- Ilanit Allen
- Auditors
- WOLF & COMPANY, P.C.
Latest News for CTXR
Upcoming Events for CTXR
Q2 2024 Citius Pharmaceuticals Inc Earnings Release
Q3 2024 Citius Pharmaceuticals Inc Earnings Release
Similar to CTXR
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:05 UTC, shares in Citius Pharmaceuticals are trading at $0.75. This share price information is delayed by 15 minutes.
Shares in Citius Pharmaceuticals last closed at $0.75 and the price had moved by -45.33% over the past 365 days. In terms of relative price strength the Citius Pharmaceuticals share price has underperformed the S&P500 Index by -54.51% over the past year.
The overall consensus recommendation for Citius Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Citius Pharmaceuticals does not currently pay a dividend.
Citius Pharmaceuticals does not currently pay a dividend.
Citius Pharmaceuticals does not currently pay a dividend.
To buy shares in Citius Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.75, shares in Citius Pharmaceuticals had a market capitalisation of $120.02m.
Here are the trading details for Citius Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CTXR
Based on an overall assessment of its quality, value and momentum Citius Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Citius Pharmaceuticals is $5.33. That is 606.52% above the last closing price of $0.75.
Analysts covering Citius Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.21 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Citius Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -7.87%.
As of the last closing price of $0.75, shares in Citius Pharmaceuticals were trading -7.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Citius Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Citius Pharmaceuticals' management team is headed by:
- Leonard Mazur - CHM
- Myron Holubiak - PRE
- Jaime Bartushak - CFO
- Myron Czuczman - EVP
- Ilanit Allen - VPR
- Howard Safir - LED
- Suren Dutia - IND
- Eugene Holuka - IND
- William Kane - IND
- Carol Webb - IND